Related Experiment Video
Updated: Aug 10, 2026
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
Prophylaxis of Mycobacterium avium complex bacteremia in patients with AIDS
1Division of Infectious Diseases, Veterans Administration Medical Center, Washington, D.C. 20422.
Abstract:
Prevention of opportunistic infections is an integral part of caring for patients infected with human immunodeficiency virus. Mycobacterium avium complex (MAC) bacteremia can cause severe morbidity and excess mortality among these patients. Controlled trials of rifabutin for the prophylaxis of MAC bacteremia have been completed. Rifabutin reduced the incidence of MAC bacteremia by approximately one-half and, when disseminated disease due to MAC (DMAC) did develop, reduced the frequency of associated clinical symptoms. Moreover, prophylaxis with rifabutin was well tolerated. Prophylaxis of MAC bacteremia with macrolide antibiotics is currently being investigated, but no data from large-scale prospective trials are yet available. On the basis of trials completed thus far, the U.S. Public Health Service has recently recommended the use of rifabutin (300 mg/d) as prophylaxis for MAC bacteremia in patients with fewer than 100 CD4+ lymphocytes/mm3. The widespread use of this prophylactic regimen could reduce the rates of morbidity and mortality caused by DMAC. However, rifabutin must be administered only after careful consideration of the circumstances of individual patients. Potential drug interactions, cost, and compliance are important factors in the decision about which patients should receive prophylaxis.
Insights
Rifabutin significantly reduces Mycobacterium avium complex bacteremia in HIV patients, lowering disease incidence and symptoms. This prophylaxis is well-tolerated and recommended for eligible patients.
Area of Science:
- Infectious Diseases
- Immunology
- Pharmacology
Background:
- Opportunistic infections are a major concern for individuals with human immunodeficiency virus (HIV).
- Mycobacterium avium complex (MAC) bacteremia leads to significant illness and death in HIV-infected patients.
- Preventive strategies are crucial for managing MAC bacteremia in this population.
Purpose of the Study:
- To evaluate the efficacy and tolerability of rifabutin for preventing MAC bacteremia in HIV patients.
- To assess the impact of rifabutin prophylaxis on disseminated MAC disease (DMAC) incidence and symptoms.
- To inform clinical recommendations for MAC bacteremia prophylaxis in HIV care.
Main Methods:
- Controlled trials were conducted to assess rifabutin's effectiveness in MAC bacteremia prevention.
- Data from prospective trials were analyzed to determine incidence reduction and symptom frequency.
- Tolerability and potential adverse effects of rifabutin prophylaxis were monitored.
Main Results:
- Rifabutin approximately halved the incidence of MAC bacteremia.
- Rifabutin reduced the frequency of clinical symptoms when DMAC occurred.
- Rifabutin prophylaxis was generally well-tolerated by patients.
Conclusions:
- Rifabutin (300 mg/d) is recommended by the U.S. Public Health Service for MAC bacteremia prophylaxis in HIV patients with <100 CD4+ cells/mm3.
- Widespread use of rifabutin prophylaxis can decrease MAC-related morbidity and mortality.
- Individual patient factors, including drug interactions, cost, and compliance, require careful consideration before initiating rifabutin therapy.
Related Concept Videos
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:27Cryptococcal Meningitis
01:28Amebiasis